LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-118’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LP-118 overview

LP-118 is under development for the treatment of refractory and relapsed non-Hodgkin's lymphoma including marginal zone B-cell lymphoma (MZL), relapsed or refractory B-cell lymphoma and advanced or metastatic solid tumors, follicular lymphoma(FL), diffuse large B cell lymphoma (DLBCL), small lymphocytic lymphoma (SLL), adult T cell lymphoma (ATLL), chronic myelomonocytic leukemia , mantle cell lymphoma, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), multiple myeloma, Richter transformation chronic lymphocytic leukemia, T cell prolymphocytic Leukemia, B-cell acute myeloid lymphoma, relapsed and refractory acute lymphocytic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, unspecified b-cell lymphomas, natural killer cell lymphomas, T-cell lymphomas and myelofibrosis. It is administered through oral route.

For a complete picture of LP-118’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.